There was no evidence that the effects of canagliflozin on the kidney, cardiovascular and HF outcomes varied by the baseline level of the plasma biomarkers (all p values for heterogeneity >0.15), except for TNFR-2 with the kidney outcome (p value for heterogeneity = 0.03). This evidence concerns the gene TNFRSF1B and hydrops fetalis.